Cresco Labs Inc. (OTCMKTS:CRLBF) Receives Consensus Rating of “Moderate Buy” from Brokerages

Cresco Labs Inc. (OTCMKTS:CRLBF) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $2.50.

A number of research analysts recently weighed in on the stock. Atb Cap Markets downgraded shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research report on Monday. Roth Capital upgraded Cresco Labs to a “strong-buy” rating in a report on Sunday, November 10th. Finally, Cormark downgraded Cresco Labs from a “moderate buy” rating to a “hold” rating in a research note on Monday, November 11th.

Cresco Labs Stock Performance

Shares of CRLBF stock opened at $0.98 on Friday. The company has a market capitalization of $475.94 million, a P/E ratio of -4.88 and a beta of 1.73. Cresco Labs has a 52 week low of $0.96 and a 52 week high of $2.65. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The company’s 50 day moving average price is $1.37 and its two-hundred day moving average price is $1.57.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.